EUVIMEDDescoperă EUVIMED
Open access · CC BY 4.0

Omalizumab Therapy Results in Defined Behavioural Changes and Improvements in Quality of Life in Solar Urticaria

Donna Parkin, Elizabeth J Marjanovic, Mark D Farrar iD, Lesley E Rhodes iD, Kirsty J Rutter iD

Photodermatology, Photoimmunology & Photomedicine · 2026-05 · 42 (3)

DOI: 10.1111/phpp.70088 ↗

At a glance

Journal article in Photodermatology, Photoimmunology & Photomedicine, published online on 2026-04-10. Written by Donna Parkin and 4 co-authors. Institution: Photobiology Unit, Dermatology Centre, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre…. Major MEDLINE topics: Omalizumab, Quality of Life, Urticaria, Solar, Anti-Allergic Agents. 26 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Institute for Health and Care Research Manchester Biomedical Research Centre, British Skin Foundation, Manchester Biomedical Research Centre.

RezumatSubjectsDate bibliograficeCiteRelated studies

Abstract (original language)

Background

Solar urticaria is a rare photodermatosis in which exquisite photosensitivity can require extreme behavioural adaptations, resulting in a substantial impact on quality of life (QoL). Omalizumab therapy has been demonstrated to improve several clinical outcome measures, but the impact on behavioural measures is poorly understood. Our objectives were to examine daylight exposure behaviours and QoL measures pre‐ and post‐omalizumab therapy.

Methods

Daylight exposure diaries were completed by n = 5 patients with solar urticaria and n = 7 healthy participants during different seasons in England, UK (51.1–53.5 o N). These incorporated a range of measures, including time spent outdoors and clothing worn, and Dermatology Life Quality Index (DLQI) data were also collected.

Results

Prior to omalizumab, patients spent less time outdoors in sunny vs. non‐sunny conditions in spring (mean 10 vs. 29 min/day, p < 0.05) and less than healthy volunteers (44 min in sunny conditions/day). On omalizumab, patients increased their time outdoors in sunny conditions, reaching similar levels to healthy volunteers in spring (45 min/day) and further increasing to 85 min/day in summer. This was accompanied by fewer days with symptoms (symptoms on 75% days in spring pre‐omalizumab vs. 26% days in summer on omalizumab), an apparent doubling of skin surface area exposure and substantial improvement in patients' QoL (mean past‐year DLQI pre‐omalizumab vs. past‐week summer on omalizumab 22 vs. 5, p < 0.001).

Conclusion

Omalizumab therapy was associated with behavioural changes that increase daylight exposure, accompanied by improved QoL. This study highlights the importance of considering a range of outcome measures in assessing response to therapy.

Subjects

MeSH terms (MEDLINE)

OmalizumabQuality of LifeUrticaria, SolarAnti-Allergic AgentsSunlightHumansFemaleMaleAdultMiddle Aged

Author keywords

omalizumabphotosensitivity disordersquality of lifesolarsun exposure behavioururticaria

Substances

OmalizumabAnti-Allergic Agents

Authors and institutions

  • Photobiology Unit, Dermatology Centre, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre, Greater Manchester, UK.
  • The Centre for Dermatology Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, NIHR Manchester Biomedical Research Centre, The Unive…

ORCID profiles: Mark D Farrar, Lesley E Rhodes, Kirsty J Rutter

Funding

  • National Institute for Health and Care Research Manchester Biomedical Research Centre
  • British Skin Foundation
  • Manchester Biomedical Research Centre

Cite

APA

Parkin, D., Marjanovic, E. J., Farrar, M. D., Rhodes, L. E., & Rutter, K. J. (2026). Omalizumab Therapy Results in Defined Behavioural Changes and Improvements in Quality of Life in Solar Urticaria. Photodermatology, Photoimmunology & Photomedicine, 42(3). https://doi.org/10.1111/phpp.70088

Vancouver

Parkin D, Marjanovic EJ, Farrar MD, Rhodes LE, Rutter KJ. Omalizumab Therapy Results in Defined Behavioural Changes and Improvements in Quality of Life in Solar Urticaria. Photodermatology, Photoimmunology & Photomedicine. 2026;42(3). doi:10.1111/phpp.70088

BibTeX
@article{Parkin2026,
  author = {Parkin, Donna and Marjanovic, Elizabeth J and Farrar, Mark D and Rhodes, Lesley E and Rutter, Kirsty J},
  title = {Omalizumab Therapy Results in Defined Behavioural Changes and Improvements in Quality of Life in Solar Urticaria},
  journal = {Photodermatology, Photoimmunology & Photomedicine},
  year = {2026},
  volume = {42},
  number = {3},
  doi = {10.1111/phpp.70088}
}
Start for free →